Test of ovarian cancer multiplex xMAP technology panel

Anticancer Research

Volumn 29, Issue 2, 2009, Pages 573-576

  Vrzalova, Jindra ^a,c   Prazakova, Marketa ^a,c   Novotny, Zdenek ^b   Topolcan, Ondrej ^a,c   Casova, Miroslava ^a   Holubec Jr , Lubos ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Faculty Hospital in Pilsen   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Multiplex; Ovarian cancer; Panel; Tumour markers

Indexed keywords

CA 125 ANTIGEN; LEPTIN; MACROPHAGE MIGRATION INHIBITION FACTOR; OSTEOPONTIN; PROLACTIN; SOMATOMEDIN B; THYMIDINE KINASE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MULTIPLEX XMAP TECHNOLOGY PANEL; OVARY CANCER; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; EPIDIDYMAL SECRETORY PROTEINS; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PEPTIDES; PROTEIN ARRAY ANALYSIS; THYMIDINE KINASE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 61449154695     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Johnson CC, Kessel B, Riley TL, Ragard LR, Williams CR, Xu JL and Buys SS: The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Prostate, Lung, Colorectal and Ovarian Cancer Project Team. Gynecol Oncol 110(3): 383-389, 2008.
2. Woolas RP, Conaway MR, Xu F, Jacobs IJ, Yu Y, Daly L, Davies AP, O'Briant K, Berchuck A, Soper JT et al: Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol 59(1): 111-116, 1995.
3. Kellar KL and Iannone MA: Multiplexed microsphere-based flow cytometric assays. Exp Hematol 30(11): 1227-1237, 2002.
4. Yurkovetsky Z, Ta'asan S, Skates S, Rand A, Lomakin A, Linkov F, Marrangoni A, Velikokhatnaya L, Winans M, Gorelik E, Maxwell GL, Lu K and Lokshin A: Development of a multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol 107(1): 58-65, 2007.
5. Yurkovetsky ZR, Kirkwood JM, Edington HD, Marrangoni AM, Velikokhatnaya L, Winans MT, Gorelik E and Lokshin AE: Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 13(8): 2422-2428, 2007.
6. Nolen BM, Marks JR, Ta'san S, Rand A, Luong TM, Wang Y, Blackwell K and Lokshin AE: Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer. Breast Cancer Res 10(3): R45, 2008.
7. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE and Mor G: Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14(4): 1065-1072, 2008.
8. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, Yue L, Bray-Ward P and Ward DC: Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 102(21): 7677-7682, 2005.
9. Thorpe JD, Duan X, Forrest R, Lowe K, Brown L, Segal E, Nelson B, Anderson GL, McIntosh M and Urban N: Effects of blood collection conditions on ovarian cancer serum markers. PloS ONE 2(12): e1281, 2007.
10. Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, Malinowski DP, Fischer TJ and Berchuck A: Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol 110(3): 374-82, 2008.
11. Gagnon A and Ye B: Discovery and application of protein biomarkers for ovarian cancer. Curr Opin Obstet Gynecol 20(1): 9-13, 2008.
12. Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST and Farias-Eisner R: The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 199(3): 215-223, 2008.
13. Tsigkou A, Marrelli D, Reis FM, Luisi S, Silva-Filho AL, Roviello F, Triginelli SA and Petraglia F: Total inhibin is a potential serum marker for epithelial ovarian cancer. J Clin Endocrinol Metab 92(7): 2526-2531, 2007.
14. Pyle-Chenault RA, Stolk JA, Molesh DA, Boyle-Harlan D, McNeill PD, Repasky EA, Jiang Z, Fanger GR and Xu J: VSGP/F-spondin: a new ovarian cancer marker. Tumour Biol 26(5): 245-257, 2005.
15. Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW, McIntosh MW, Brown PO, Nelson BH and Urban N: Systematic evaluation of candidate blood markers for detecting ovarian cancer. PLoS ONE 3(7): e2633, 2008.
16. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N and Hellström KE: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 63: 3695-3700, 2003.
17. Singer CF, Mogg M, Koestler W, Pacher M, Marton E, Kubista E and Schreiber M: Insulin-like growth factor (IGF)-I and IGF-II serum concentrations in patients with benign and malignant breast lesions: free IGF-II is correlated with breast cancer size. Clin Cancer Res 10: 4003-4009, 2004.
18. Mathur SP, Mathur RS, Gray EA, Lane D, Underwood PG, Kohler M and Creasman WT: Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF-binding protein 3 (IGF-BP3) and VEGF-A. Gynecol Oncol 98(3): 467-483, 2005.
19. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, Berkowitz RS, Cramer DW and Mok SC: Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 287(13): 1671-1679, 2002.
20. Fedarko NS, Jain A, Karadag A, VanEman MR and Fisher LW: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate and lung cancer. Clin Cancer Res 7: 4060-4066, 2001.